Coronary disease & ACSTrial design
Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2)
- investigator-initiated, multicenter, randomized controlled trial
- design and rationale (protocol)
- 1:1 randomization
Study context
- Population
- Patients using direct oral anticoagulation (DOAC) and scheduled for elective invasive coronary angiography (ICA) or percutaneous coronary intervention (PCI)planned number to be randomized
- Participants
- 1,270 patients
- Planned comparison
- continuing DOAC therapy vs temporary interruption
- Primary endpoint
- In-hospital bleeding, Bleeding Academic Research Consortium (BARC) type 2, 3, or 5
- Follow-up
- In-hospital
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2). Am Heart J. Published 27 April 2026. doi:10.1016/j.ahj.2026.107462
Summarised from the published abstract; every number is checked against it